Exhibit 99.1 

J.P. Morgan Healthcare Conference | January 15, 2020 | 1 Compelling and Rare Investment Thesis EXECUTION Short - term to Mid - term: 2 – 3x Low Risk Research Value Creation x Adoption pace; $0 to $57M in 5 yrs x Technology and application validation x Low regulatory or reimbursement risk x Proven management, board and founder x Strong economic profile, early penetration x Solid balance sheet; multiple growth catalysts x Investor business development engine / PPH x IP strength and Nextgen roadmap ASPIRATION Mid - term to Long - term: 10 – 15x High Value Diagnostic Disruption x Precision health body of evidence x Disruptive “sensitivity” in all “omics” x Regained 100% of diagnostic rights x Blood based, low cost and high optionality x Neuro toolkit, liquid biopsy, single cell, drug rescue x Short - term LDT, Longer - term IVD and POC x Abbott, Quest, Labcorp , Siemens, Roche x Management team well positioned

J.P. Morgan Healthcare Conference | January 15, 2020 | 2 Scientific Research & Excellence in Execution driving Performance PUBLICATIONS* MARKERS* Revenue $m 363 155 159 104 56 15 206 18 409 16 17 19 677 Other Neurology Oncology 68 218 36 190 15 16 18 17 19 133 53 259 322 * Cumulative x Compelling rev growth & GM expansion x Launched HD - X and SP - X x Full Year Consumables growth 75%+ x Raised ~$120m growth capital x Acquired Uman Dx to protect pivotal brain biomarker x Siemens Nf - L license & Techne deal x Nf - L in a record 50 pubs at ECTRIMS (MS) and strong showing at AAIC (AD) x Incredible publication and new biomarker growth x Strengthened team / new facility x Lead sponsor at Powering Precision Health Summit 2019 10.9 18 15 37.6 16 17 19 12.2 17.6 22.9 +44% +30% +64% Q1 Q2 Q3 Q4 % Growth +64% +57% +41% +46% “ 4% Q4 2019 and FY 2019 information are preliminary, unaudited estimates and are subject to the Company’s normal quarter and year - en d close procedures. These procedures and the audit of the Company’s financial statements for the year ended December 31, 2019 are on goi ng and could result in changes to such estimated information. +51% “ 1% 56.7 “ 0.4 15.9 “ 0.4

J.P. Morgan Healthcare Conference | January 15, 2020 | 3 Neurology Oncology Strategy Financials Technology 50%+ utilization SP - X Launch IVD partnership Accelerate via M&A LT Growth: 40% GM: +300 bps Inst Growth: 25%+ 100x sensitivity increase by YE 2021 • Launched HD - X early • Launched SR - X 1.1 • ~60% Utilization • Launched SP - X • Sold 10 units • PPH Onco track • Acquired Uman • Siemens License • 50+ drug trials • Growth 50%+ • YTD GM: +400 bps • Instrument 50%+ • 40X defined / prototype 2019 Progress vs. Goals * Non - GAAP Item: Reconciliation for these items provided in the appendix to this presentation